

Theranexus announces the nomination of Werner Rein as Chief Medical Officer (CMO)

Lyon, France, August 29, 2017—Theranexus, a biopharmaceutical company providing innovative therapies for central nervous system (CNS) disorders, has bolstered its executive team through the nomination of Werner Rein, M. D. to the position of Chief Medical Officer.

Dr Rein will be in charge of the clinical development strategy of Theranexus' portfolio of drug candidates. As a seasoned physician with expertise in neurology and psychiatry, Dr. Rein has over 20 years of international experience working in the field of CNS diseases. He held a number of roles in the management of drug development programmes in the pharmaceutical industry and most recently was Sanofi's Global Vice President for Clinical Research in Psychiatry.

He supervised all stages of clinical development for over ten drugs, including interactions with the regulatory agencies in charge of drug registrations in the three main territories of the pharmaceutical industry: the United States (FDA), Europe (EMA), and Japan (PMDA). He thus played an active role in the market approval of amisulpride (Solian®), an antipsychotic; and extended-release zolpidem (Stilnox CR® / Ambien CR®), a sleep medication. At Sanofi, Dr. Rein also served as a due diligence team leader during multiple product assessments conducted for the purpose of in-licensing or acquisition transactions.

'We are delighted to have Werner on board alongside us as we are growing the company,' said Theranexus' CEO Franck Mouthon. 'His extensive knowledge of CNS disorders and experience with the drug development process in this therapeutic area will strengthen our company's ability to lead ambitious clinical development programmes. Having Werner by our side also allows us to widen our strategic vision for such programmes.'

'I am thrilled to join Theranexus,' said Dr. Rein. 'I am convinced the company has a high-calibre team and a therapeutic rationale that offers great potential for clinical applications. I very much look forward to furthering this fascinating and innovative approach.'

Dr Rein taught at Germany's prestigious University of Tübingen.

About Theranexus

Theranexus is a clinical-stage biopharmaceutical company founded in 2013 and spun-out from the French Atomic Energy Commission (CEA). Capitalizing on the prominent role non-neuronal cells play in neuron activity, Theranexus designs and develops groundbreaking drugs that act simultaneously on both cell types within the brain. Its clinical objective is to provide innovative and effective therapeutic solutions for the treatment of neurological disorders.

By choosing to apply its concept through the combination of preexisting drugs, Theranexus is able to drastically shorten development time and considerably increase the chances of success of its R&D process.

Theranexus has financial backing from Auriga Partners, Sofimac Partners, CEA Investissement, and Kreaxi.

<http://www.theranexus.com>

Press contact

Florence Portejoie

FP2COM

Mob. : + 33 (0) 6 07 76 82 83

Email : fportejoie@fp2com.fr